China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced approval by the United States Adopted Names (USAN) Council to name its ISM001-055 as rentosertib. This groundbreaking drug candidate for idiopathic pulmonary fibrosis (IPF) represents a milestone in AI-driven drug discovery.
Rentosertib’s Development and Clinical Results
Rentosertib is the world’s first drug discovered via generative AI in terms of target and molecular structure. The drug candidate took only 18 months from target discovery to preclinical candidate compound nomination, showcasing the efficiency of Insilico Medicine’s AI platform. The drug has completed multiple clinical studies with encouraging results.
Clinical Trial Highlights
Phase I clinical trials demonstrated good safety, tolerability, and pharmacokinetics. Phase IIa clinical trials further revealed that rentosertib improved patients’ forced vital capacity (FVC) in a dose-dependent manner. Additionally, quality of life indicators, such as the Leicester Cough Questionnaire (LCQ) and overall respiratory symptoms, showed significant improvement, with the drug proving to be safe and well-tolerated.-Fineline Info & Tech
Leave a Reply